Compare TS & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TS | RMD |
|---|---|---|
| Founded | 2001 | 1989 |
| Country | Luxembourg | United States |
| Employees | 24875 | 10600 |
| Industry | Steel/Iron Ore | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8B | 32.2B |
| IPO Year | N/A | N/A |
| Metric | TS | RMD |
|---|---|---|
| Price | $59.75 | $206.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $58.80 | ★ $292.56 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.80% | 1.13% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.53 | $10.60 |
| Revenue Next Year | $3.59 | $7.41 |
| P/E Ratio | ★ $12.59 | $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.00 | $198.64 |
| 52 Week High | $64.33 | $293.81 |
| Indicator | TS | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.81 | 32.97 |
| Support Level | $56.88 | $198.64 |
| Resistance Level | $60.01 | $260.21 |
| Average True Range (ATR) | 0.99 | 5.39 |
| MACD | -0.56 | -0.69 |
| Stochastic Oscillator | 30.05 | 28.51 |
Tenaris SA is engaged in the manufacture and supply of steel pipe products and related services for the energy industry and other industrial applications. The company has one reportable segment, Tubes, which includes the production and sale of steel tubular products such as OCTG, line pipe, and mechanical and structural tubes, mainly for the oil and gas industry. It operates an integrated network of manufacturing, research, and service facilities across the Americas, Europe, the Middle East, Asia, and Africa.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.